Form 4: Macrogenics COO Eric Risser Reports Stock Transactions
SEC Form 4 Filing
Chief Operating Officer of Macrogenics, Eric Risser, reports the acquisition and disposal of common stock and restricted stock units.
Summary
- On February 15, 2025, Eric Risser, the Chief Operating Officer of Macrogenics Inc., reported transactions involving the company's stock.
- Risser acquired 16,665 shares of common stock upon the vesting of restricted stock units.
- Simultaneously, Risser disposed of 6,433 shares of common stock at a price of $2.56 per share.
- Following these transactions, Risser directly owns 55,989 shares of Macrogenics common stock.
- The reported transactions also involve restricted stock units, with 16,665 units converting into common stock.
- These restricted stock units are part of a grant from February 15, 2023, where 33% vested on February 15, 2024, and 33% will vest annually thereafter.
Sentiment
Score: 5
Explanation: The document reflects routine insider transactions related to stock-based compensation, with no indication of unusual or concerning activity. It's a neutral event.
Industry Context
Form 4 filings are standard practice for reporting insider transactions, providing transparency to investors regarding the buying and selling activities of company executives and directors. This filing indicates routine transactions related to stock-based compensation.
Comparison to Industry Standards
- Form 4 filings are a standard regulatory requirement for publicly traded companies in the US.
- Similar filings are made by executives at companies like Amgen, Biogen, and Gilead Sciences when they trade their company's stock.
- The vesting schedule of the restricted stock units (33% annually) is a common practice in the biotech industry for executive compensation.
Stakeholder Impact
- The transactions provide transparency to shareholders regarding executive compensation and stock ownership.
- The disposal of shares could have a minor impact on the stock price, but is likely offset by the routine nature of the transactions.
Key Dates
| Date | Description |
|---|---|
| 02/15/2023 | Date of grant of 50,000 restricted stock units, vesting over three years. |
| 02/15/2024 | First vesting date of the restricted stock units (33%). |
| 02/15/2025 | Date of reported transactions: acquisition of stock through vesting of RSUs and disposal of shares. |
| 02/19/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.